Sequential therapy with cefuroxime and cefuroxime-axetil for community-acquired lower respiratory tract infection in the oldest old

Aging Clinical and Experimental Research

Volumn 20, Issue 1, 2008, Pages 81-86

  Flamaing, Johan ^a   Knockaert, Daniël ^a   Meijers, Björn ^a   Verhaegen, Jan ^a   Peetermans, Willy E ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Elderly; Lower respiratory tract infection; Sequential antibiotic therapy

Indexed keywords

C REACTIVE PROTEIN; CEFUROXIME; CEFUROXIME AXETIL;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE;

EID: 40849113328     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324752     Document Type: Article

References (27)

1. Greenberg SB. Viral respiratory tract infections in elderly patients and patients with chronic obstructive pulmonary disease. Am J Med 2002; 112: 28S-32S.
2. Flamaing J, Engelmann I, Joosten E, Van Ranst M, Verhaegen J, Peetermans WE. Viral lower respiratory tract infection in the elderly: a prospective in-hospital study. Eur J Clin Microbiol Infect Dis 2003; 22: 720-5.
3. Johnson D, Carriere KC, Sin Y, Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community acquired pneumonia is associated with decreased in-hospital mortality. J Clin Pharm Ther 2004; 29: 231-9.
4. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54.
5. Lelekis M, Gould IM. Sequential antibiotic therapy for cost containment in the hospital setting: why not? J Hosp Infect 2001; 48: 249-57.
6. Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs 2002; 62: 309-17.
7. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4: 112-24.
8. Siegel RE, Halpem NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 1996; 110: 965-71.
9. Iakovlev SV, Suvorova MP, Dvoretskii LI, Vlasenko NA, Shakhova TV. Stepwise therapy of community-acquired pneumonia: results of cefuroxime and cefuroxime axetil study. Antibiot Khimioter 1998; 43: 7-11.
10. Vogel F, Droszcz W, Vondra V, Reisenberg K, Marr C, Staley H. Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40: 863-71.
11. Van den Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997; 112: 406-15.
12. Siegel RE, Alicea M, Lee A, Blailock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community acquired pneumonia: a prospective, randomized, double blind study. Am J Ther 1999; 6: 217-22.
13. Brambilla C, Kastanakis S, Knight S, Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992; 11: 118-24.
14. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72.
15. Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160: 1294-300.
16. Stille W, Sass R, Klinge R, Loos U, Althoff PH, Kullmann KH. Ceftriaxone i.v./cefetametpivoxil versus cefuroxim i.v./cefuroximaxetil: pharmacoeconomic comparison of intravenous-oral sequential therapy in patients with community-acquired pneumonia. Chemotherapie J 2000; 9: 87-92.
17. Wilson R, Langan C, Ball P, Bateman K, Pypstra R, The Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Resp Med 2003; 97: 242-9.
18. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcome Research Team cohort study. Arch Intern Med 1997; 157: 47-56.
19. Torres OH, Munoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc 2004; 52: 1603-9.
20. Mundy LM, Leed TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124: 883-9.
21. Louis TJ. Intravenous to oral stepdown antibiotic therapy: another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5: 45C-50C.
22. Verhaegen J, Van de Ven J, Verbiest N, Van Eldere J, Verbist L. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Belgium - update (1994-1998). Clin Microbiol Infect 2000; 6: 308-15.
23. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
24. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs 2001; 61: 1455-500.
25. Delmée M, Carpentier M, Glupczynski Y, et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. Acta Clin Belg 1996; 51: 237-43.
26. Veyssier P, Darchis JP, Devillers A. Pharmacokinetics of cefuroxime-axetil after oral administration during six days treatment in elderly patients. Therapie 1988; 43: 355-9.
27. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163: 317-23.